Global Almonertinib Mesylate Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Almonertinib Mesylate market size was valued at US$ 216 million in 2025 and is forecast to a readjusted size of US$ 700 million by 2032 with a CAGR of 17.4% during review period.
In 2025, global production of almonertinib mesilate reached approximately 1.02 million units.Almonertinib Mesylate is an oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), primarily used for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations or the T790M resistance mutation. It works by selectively inhibiting the kinase activity of mutant EGFR, thereby blocking tumor cell proliferation and survival signaling pathways and suppressing tumor growth.
Almonertinib mesylate is characterized by high selectivity for mutant EGFR, good central nervous system penetration, and a relatively manageable safety profile, making it clinically valuable in the treatment of advanced non-small cell lung cancer.
Almonertinib Mesylate, as a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), operates in a rapidly evolving segment of the non-small cell lung cancer (NSCLC) targeted therapy market, particularly demonstrating strong competitiveness in patients with EGFR mutations and T790M resistance mutations. With the large population of lung cancer patients and the continuous improvement in genetic testing penetration, the demand for precision therapy is steadily increasing, providing a solid market foundation for this class of drugs.
From a competitive landscape perspective, imported originator drugs represented by Osimertinib have long dominated the market. However, almonertinib mesylate, leveraging its domestic R&D advantages, competitive pricing, and potential efficacy in patients with central nervous system metastases, is gradually gaining market share in China.
On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although healthcare cost-control measures and volume-based procurement policies continue to exert pressure on pricing. From a competitive standpoint, multiple third-generation EGFR-TKIs and next-generation targeted therapies from both domestic and international companies are continuously entering the market, intensifying competition. Therefore, the future market performance of almonertinib mesylate will depend on its penetration in first-line treatment, expansion of indications (such as adjuvant therapy), and the accumulation of real-world evidence, as well as its overall competitive balance in terms of efficacy, safety, and pricing.
This report is a detailed and comprehensive analysis for global Almonertinib Mesylate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Almonertinib Mesylate market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Almonertinib Mesylate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Almonertinib Mesylate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Almonertinib Mesylate market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Almonertinib Mesylate
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Almonertinib Mesylate market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Jiangsu Hansoh Pharmaceutical Group, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Almonertinib Mesylate market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
55mg
110mg
Market segment by Application
Non-small Cell Lung Cancer (NSCLC)
Third-generation Tyrosine Kinase Inhibitor (TKI)
Others
Major players covered
Jiangsu Hansoh Pharmaceutical Group
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Almonertinib Mesylate product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Almonertinib Mesylate, with price, sales quantity, revenue, and global market share of Almonertinib Mesylate from 2021 to 2026.
Chapter 3, the Almonertinib Mesylate competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Almonertinib Mesylate breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Almonertinib Mesylate market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Almonertinib Mesylate.
Chapter 14 and 15, to describe Almonertinib Mesylate sales channel, distributors, customers, research findings and conclusion.